Data from a preclinical study showed that concurrent ARID1A-PIK3CA mutations in endometrial and ovarian cancers promote ovarian clear cell tumorigenesis through the tumorigenic inflammatory cytokine signaling pathway, which can be blocked by IL-6 inhibitors (77). Here, PIK3CA is linked to ovarian carcinoma.